From the lab to the market: deep tech entrepreneurs talk about their journey
Although Switzerland is championed as a world leader at innovation, it is less celebrated for its start-up culture. Does the country have what it takes to produce, finance and nurture the technology of the future? A new documentary explores that question. Our spin-off Gaia Membranes talks about their experiences as a swiss startup.
ELDICO Scientific AG closes seed financing round of CHF 1.5 million
One year following its incorporation, ELDICO Scientific, benefitting from research and development cooperations with the PSI, has successfully closed a seed funding round. The company raised almost CHF 1.5 million from private and institutional investors, BERNINA BioInvest, several industry-savvy private investors, the Aargauische Kantonalbank (AKB) and Venture Kick. ELDICO will be launching the first electron diffractometer specially designed for nano-crystallographic research.
VentureKick: PSI Fellow wins 40'000 CHF
The PSI Fellow Florian Döring (PostDoc in the «Photon Science» Division) receives Venture Kick's second stage of pre-seed funding, network support, and entrepreneurial training.
Domain Wall Logic (Spintronics) using CMOS compatible production processes
Scientists from Paul Scherrer Institute (PSI) and ETH Zurich have taken a big step towards making Spintronic devices manufacturable based on processes used in CMOS microchip production. So called Domain Wall Logic circuits can store many different non-volatile magnetic states (bits) directly within the circuit. Such a logic-in-memory device would restart in the exact state it had before a power loss and could immediately continue whatever process was underway at the time of the power loss. The team led by Professors Gambardella and Heyderman demonstrated a working proof of concept Domain Wall Logic Adder that fundamentally merges storage and processing operations in a single circuit opening the doors Spintronic chips.
Supporting the Worlds Scientist in their efforts to against COVID-19
The current Coronavirus pandemic has scientists worldwide collaborating extensively to learn about the virus and develop vaccines as well as therapeutics. Together with scientific and industrial partners including the Paul Scherrer Institute, our spin-off leadXpro has developed a method to provide the research and development community with SARS-CoV-2 M protein. This M protein that is an important part of the virus capsule is a potential target for drugs against the virus. We are happy to invite interested parties wishing to receive protein to contact leadXpro.
«Switzerland Innovation Tech4Impact»: Call for Proposals for Groundbreaking Innovation
The current pandemic is also having a severe impact on Switzerland as a business loca-tion. That is why it is particularly important to invest in innovation now. With this in mind, “Switzerland Innovation” Foundation is launching its first major call for proposals to-gether with renowned partners from the Swiss economy. Funding will be provided for in-novation projects that address the most pressing problems of our time.
The PSI Spin-Off Araris Biotech AG is one of the 10 winners of this year’s Venture Leaders Life Science award
As a winner, Araris will take part in the Swiss Biotech Day 2020 and a one-week roadshow to Boston, where Araris along with the other Venture Leaders will be pitching to key US investors and meeting leaders and experts of the biotech and medtech industries. Boston is one of the world’s major life sciences hubs and the ideal springboard for ambitious startups on their way to global expansion.
Swiss BIC of CERN Technologies calls for innovative ideas – deadline 30th April
For the third time, Switzerland Innovation Park Innovaare in Villigen/AG is hosting the call for proposals for high-tech business ideas that incorporate accelerator technologies into their products.
ANAXAM has Officially Launched
Anaxam is a technology transfer center created as a collaboration between PSI, the FHNW, the SNI and the Kanton of Aargau. Created to provide simplified access for industry to the large research facilities at PSI and focused on delivering services to support Advanced Manufacturing, both in the improvement of existing products as well as with manufacturing processes. ANAXAM has Officially Launched today 2019.12.01.
Park Innovaare: Groundbreaking Event
Today, PARK INNOVAARE steps into a new era. Accompanied by more than 200 guests including partners, shareholders, and key politicians, scientists and entrepreneurs, PARK INNOVAARE broke the ground to the construction of its new innovation campus. An investment of 155 CHF million by CPV/CAP Coop Pension Fund has brought this construction project to fruition
Araris Biotech AG closes seed financing round of CHF 2.5 million
Araris Biotech AG (a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich) announced today the closing of an oversubscribed seed financing round of CHF 2.5 million with participation of Swiss investors Redalpine, Schroder Adveq and VI Partners. The proceeds will be used to develop a pipeline of proprietary antibody-drug conjugates (ADCs)
Park Innovaare: Financing of new Campus is secured
After an intensive round of negotiations, Park Innovaare concluded an investment agreement with CPV/CAP Pensionskasse Coop for the realization of the new buildings. With this agreement, Park Innovaare has come another step closer to realizing its goal: a state-of-the-art infrastructure of about 38’000 sqm next to the Paul Scherrer Institute PSI that is ideal for industrial R&D projects.
Congratulations to Debiopharm
Debiopharm – a Swiss pharma company that has licensed-in one of PSIs developments -a compound with high potential for cancer diagnosis & therapy has been nominated for the “2019/2020 Swiss Biotech Sucess Stories Awards”